by jtcir-auto | May 5, 2021 | Press Releases
– Q12021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets- Pivotal Phase 3DETECT(Study P02) safety and efficacy study evaluating macimorelin diagnostic for CGHD on track to...
by jtcir-auto | May 5, 2021 | Press Releases
– Q12021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets- Pivotal Phase 3DETECT(Study P02) safety and efficacy study evaluating macimorelin diagnostic for CGHD on track to...
by jtcir-auto | May 3, 2021 | Press Releases
– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncologyCHARLESTON, S.C., May 03, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...
by jtcir-auto | May 3, 2021 | Press Releases
– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncologyCHARLESTON, S.C., May 03, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...
by jtcir-auto | Apr 28, 2021 | Press Releases
CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...